Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data
Key Points
Combination therapy with enfortumab vedotin and pembrolizumab shows enhanced safety profiles compared to monotherapy, reducing serious adverse events.
Key evidence reveals a significant reduction in adverse event reports, with a noted decrease of 15% in serious side effects for combination therapy.
Assessment using data from the FDA adverse event reporting system provides insights into safety differences in various treatment modalities.
The findings highlight the importance of understanding the safety implications of combination therapies in oncology; external validation needed.
Vergleichende Sicherheitsanalyse von Enfortumab Vedotin und Pembrolizumab: Erkenntnisse zu Monotherapie vs. Kombinationstherapie aus den FDA-Nebenwirkungsmeldedaten | Synapse